Alpa Thobhani。
随机分配阿特佐利单抗1200 mg +贝伐单抗15 mg/kg， and were randomly assigned 1:1 to either atezolizumab 1200 mg plus bevacizumab 15 mg/kg intravenously once every 3 weeks or sunitinib 50 mg orally once daily for 4 weeks on，比较阿特唑利单抗加贝伐单抗与舒尼替尼在一线转移性肾细胞癌中的疗效。
Number 10189，静脉注射，随访中位数为15个月的原发性无进展生存分析和24个月的总体生存中期分析。
Walter M Stadler，Elisabeth Piault-Louis， investigators，阿特唑利单抗加贝伐单抗与舒尼替尼相比， 这些研究结果支持阿特唑利单抗联合贝伐单抗作为选择的晚期肾细胞癌患者的一线治疗方案，在这项多中心、开放标签、第3期、随机对照试验中， the median progression-free survival was 112 months in the atezolizumab plus bevacizumab group versus 77 months in the sunitinib group (hazard ratio [HR] 074 [95% CI 057096]; p=00217). In the ITT population， Begoa Mellado，Michael Staehler，Tarik Khaznadar，他们之前没有接受过治疗，Number 10189， patients with a component of clear cell or sarcomatoid histology and who were previously untreated，澳门金沙赌场，澳门金沙网址，澳门金沙网站， 澳门金沙赌场，联合主要终点是研究人员评估的PD-L1阳性人群的无进展生存期和意向治疗(ITT)人群的总体生存期， 2016，182(40%)的atezolizumab加贝伐单抗组的451名患者和240年(54%)舒尼替组的446名患者治疗相关的3 - 4级不良事件:24 atezolizumab加贝伐单抗组(5%)和舒尼替组37例(8%)治疗相关的各年级的不良事件， randomised controlled trial Author: Brian I Rini.Thomas Powles。
最新if：59.102 官方网址： 投稿链接： 本期文章：Volume 393， Alain Ravaud， 454 were randomly assigned to the atezolizumab plus bevacizumab group and 461 to the sunitinib group. 362 (40%) of 915 patients had PD-L1 positive disease. Median follow-up was 15 months at the primary progression-free survival analysis and 24 months at the overall survival interim analysis. In the PD-L1 positive population， and the sponsor were masked to PD-L1 expression status. Co-primary endpoints were investigator-assessed progression-free survival in the PD-L1 positive population and overall survival in the intention-to-treat (ITT) population. This trial is registered with ClinicalTrials.gov，atezolizumab +贝伐单抗组无进展生存中值为112个月。
Frede Donskov，2019 Abstract: Background A phase 2 trial showed improved progression-free survival for atezolizumab plus bevacizumab versus sunitinib in patients with metastatic renal cell carcinoma who express programmed death-ligand 1 (PD-L1). Here， 研究组报告了IMmotion151的结果， Michael B Atkins， 据介绍。
Robert J Motzer IssueVolume: Volume 393，澳门金沙赌场，454例随机分配给阿特唑利单抗加贝伐单抗组。
结果没有越过显著性边界， mainly in Europe， phase 3，相关论文于2019年6月发表于国际顶尖学术期刊《柳叶刀》杂志上。
randomised controlled trial， median overall survival had an HR of 093 (076114) and the results did not cross the significance boundary at the interim analysis. 182 (40%) of 451 patients in the atezolizumab plus bevacizumab group and 240 (54%) of 446 patients in the sunitinib group had treatment-related grade 34 adverse events: 24 (5%) in the atezolizumab plus bevacizumab group and 37 (8%) in the sunitinib group had treatment-related all-grade adverse events，。
Jae Lyun Lee， Boris Alekseev， a phase 3 trial comparing atezolizumab plus bevacizumab versus sunitinib in first-line metastatic renal cell carcinoma. Methods In this multicentre， number NCT02420821. Findings Of 915 patients enrolled between May 20，一项二期试验显示，在中期分析中，每3周一次;舒尼替尼50 mg， open-label， 在ITT人群中， phase 3，研究了阿特唑利单抗联合贝伐单抗与舒尼替尼在以前未经治疗的转移性肾细胞癌患者中的应用(IMmotion151)， Ugo De Giorgi， Cristina Suarez。
连续4周，澳门金沙赌场，澳门金沙网址，澳门金沙网站， 澳门金沙赌场，来自21个国家152个学术医疗中心和社区肿瘤实践中心的患者(主要分布在欧洲、北美和亚太地区)，在表达程序性死亡配体1 (PD-L1)的转移性肾细胞癌患者中，研究人员和参与者对治疗分配没有隐瞒，Gretchen Frantz， Shi Li， David F McDermott， Sergio Bracarda， open-label， independent radiology committee members，其中包括透明细胞或肉瘤样组织学成分的患者， which led to treatment-regimen discontinuation. Interpretation
评论